Chapter 41: Antimycobacterial Drugs for Treating Tuberculosis and Other Diseases

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today, we are doing something a little bit different.

We know a lot of you out there aren't just listening for, you know, casual entertainment.

You're 8 .0 am, the coffee pot is empty, and the textbook currently looks like it's written in ancient Greek.

We've all been there.

I mean, the panic is real.

So we're calling this the Last Minute Lecture Series.

Exactly.

We're taking a specific, dense, high stakes chapter from a standard pharmacology text, specifically chapter 41 from Brenner and Stevens Pharmacology, sixth edition, and we are going to just tear it apart, decode it, and serve it up on a platter.

Right.

Our today is strictly on the text provided.

The title of the chapter is Antimicrobacterial Drugs for Treating Tuberculosis and Other Diseases.

It is a heavyweight chapter.

I mean, we aren't just talking about a runny nose here.

We're talking about drugs that treat some of the oldest and most persistent enemies of humanity, tuberculosis, leprosy, and those opportunistic infections that prey on the most vulnerable.

Our mission is simple.

We are going to walk through this chapter in the exact order it is written.

We're not bringing in outside research or new clinical guidelines from this morning's news.

Nope.

We are sticking to the text.

Just the book.

I'm going to be the student flagging the stuff that looks like it's going to be on the exam, the high yield concept.

And I'll be the tutor.

I'll help synthesize the data, explain those complex mechanisms, and hopefully make sense of the tables and figures so you don't have to stare at them for hours wondering what the x -axis means.

Perfect.

So grab your highlighter, metaphorically speaking, and let's dive in.

The chapter opens with a pretty grim overview of the landscape.

It says tuberculosis or TB claims a life every 10 seconds.

Yeah.

That is a terrifying statistic.

It is.

And the text makes a point to explain why it's still such a killer.

It describes a sort of perfect storm of factors.

A perfect storm.

Yeah, you have apathy, you have poverty, and you have drug resistance.

These three factors, they just combine to make TB a chronic, persistent threat,

especially in developing countries where the healthcare infrastructure might be strained.

And it mentions the HIV connection right up front, doesn't it?

It does.

It calls it a co -epidemic.

Yeah.

The HIV pandemic has posed a massive challenge because it weakens the immune system, making people vastly more susceptible to TB.

Right, of course.

And treating them together is a pharmacological puzzle, which we'll definitely get to later when we talk about drug interactions.

The text specifically notes that TB is the leading cause of death among people with HIV.

Okay, so we know the stakes are high.

The text says effective treatment requires complex regimens for at least six months.

And there's this urgent need for drugs that target dormant organisms.

Why is dormancy such a big deal here?

That is the crux of the whole chapter.

I mean, if the bacteria were always active and dividing, killing them would be relatively easy.

Standard antibiotics, they love dividing cells.

But these mycobacteria can go into a state of hibernation or dormancy where they just sit there.

Standard antibiotics just bounce off them.

So that's why it takes so long.

That's why treatment takes so long.

You're either waiting for them to wake up so you can kill them or you're trying to find a specific drug that can somehow penetrate that dormant shield.

Let's talk about the bad guys themselves.

The chapter defines mycobacteria as acid -fast bacilli.

I remember that from microbiology, but refresh us.

What does acid -fast actually imply for the drugs?

Okay, so it all refers to their cell wall.

This is the most important anatomical feature of the bug.

They have this thick waxy coat that retains dye even when you wash it with acid in the lab.

Hence acid -fast.

Hence acid -fast.

But pharmacologically, that waxy coat acts like a suit of armor.

It makes it very, very difficult for drugs to penetrate.

It's rich in something called mycolic acids, which is a term we'll hear a lot about.

Okay, mycolic acids.

Got it.

The text lists the big three pathogens we need to worry about.

Obviously, number one is mycobacterium tuberculosis or TB.

Correct.

That's the main focus of the chapter.

Then we have mycobacterium avium intracellular, which the book abbreviates as MC.

Right.

The opportunistic cousin, you could say.

And finally, leprosy or Hansen disease caused by mycobacterium leprae.

Let's start with TB.

The text breaks down the pathophysiology.

How does it get in what happens once it's there?

So transmission is via aerosol droplets, someone with active TB coughs or sneezes.

And those microscopic droplets, they just float in the air, you inhale them, and the organism settles in the pulmonary alveoli, the tiny air sacs deep in your lungs.

And then the body fights back.

It tries.

Oh, it definitely tries.

The immune system sends macrophages, those are the cleaner cells, to go and eat the bacteria.

But TB is tricky.

It actually invades the macrophage.

It gets inside the cleaner cell.

Yep.

Then the body tries to wall it off.

It aggregates connective tissue and immune cells to form a structure called a granuloma.

And the text mentions caseous lesions.

That sounds vivid.

Caseous literally means cheese -like.

It refers to the necrotic or dead tissue in the center of that granuloma.

It's soft and has a cheese -like appearance.

But here is the key concept for pharmacology.

These caseous granulomas act as a bunker.

They are avascular.

Avascular, meaning they have no blood supply.

No blood supply.

So it's hard for drugs in the bloodstream to get there.

Exactly.

And the environment inside is acidic and low in oxygen.

This protects the organism from the immune system and from chemotherapy drugs.

This is where the bacteria sit, dormant, and sequester.

So that explains the whole dormancy issue.

The text also throws out a stat about latent versus active TB.

It says about one -third of the world's population has a latent infection.

One -third.

That's billions of people.

It is staggering.

But remember, latent means asymptomatic.

The bacteria are there, but the body has them contained in those granulomas.

OK.

The text says only about 10 % of those people will eventually develop active TB.

That usually happens when the immune system slips up due to age, stress, poor nutrition, or something like HIV.

OK.

Let's move to the cousins briefly before we hit the drugs.

Atypical mycobacteria.

The text mentions M .cansassi and the M .avium intracellular complex, or MAC.

Who gets MA?

The text is specific here.

MAC is seen most frequently in immunocompromised patients, particularly those with AIDS.

It can cause pulmonary disease, lymphadenitis, which is just swollen lymph nodes, or bacteremia, where the bacteria gets into the blood.

And it's only in immunocompromised people.

Well, mostly.

It does note that even immunocompetent people can get it if they have chronic lung issues like bronchitis or emphysema.

Got it.

And the third one is leprosy, mycodycterium lepro.

This feels like a disease from the history books, but the text says there are still several hundred thousand cases.

True.

It's a fascinating organism because it grows incredibly slowly.

The disease progresses over decades.

It infects the skin and the peripheral nervous system.

And it mentions two forms.

Yes.

Lepromatous and tuberculoid leprosy.

They have different immune responses and clinical looks.

Tuberculoid is milder because the body mounts a stronger immune defense.

Lepromatous is more severe with widespread lesions because the immune response fails.

Is it really contagious?

That's a key thing to remember.

Contrary to popular belief, it's not highly contagious.

You need prolonged close contact to catch it.

Okay, we've met the enemies.

Now let's talk strategy.

Part two of our outline is the strategy of treatment.

The text lays out three specific goals for chemotherapy.

What are they?

Okay.

So goal one,

kill the bacilli rapidly.

You want to lower the bacterial load fast to stop the person from being contagious and feeling sick.

Make sense.

Goal two, eliminate the dormant or sequestered bacilli, the ones hiding in the cheese.

If you don't get these, the patient

relapses.

And goal three, prevent relapse and transmission entirely.

And to do that, we use drug regimens.

The text has a big table, table 41 .1.

For the students listening, we are going to visualize this for you because this table is essentially the clinical protocol.

Let's look at active TB.

What is the preferred therapy?

The gold standard is the four drug combination.

We often call this the R I P E regimen.

You start with four drugs,

isoniazid, rifampin, parisianamide, and ethanbutyl.

Okay, R I P E.

You give all four of these for the first two months.

This is what's called the initial phase.

Okay.

Two months of the big four.

Then what?

Then you transition to the continuation phase.

You drop two of them.

You continue with just isoniazid and rifampin for another four months.

So the total minimum treatment time is six months.

Why start with four?

Why not just pick the best one?

To prevent resistance, it's really a mathematical game.

The likelihood of a bacterium being resistant to drug A might be, say, one in a million.

The likelihood of it being resistant to drug B might also be one in a million.

Okay.

But the likelihood of it being resistant to drug A and drug B and drug C and drug D simultaneously is astronomically low.

By hitting them with four mechanisms at once, you ensure you kill even the mutants.

Got it.

Now, what about latent TB?

If I'm in that one third of the population, but I'm not sick, do I take four drugs?

No, no, that would be overkill and way too toxic.

For latent TB, the bacterial load is low.

The standard is monotherapy.

Usually it's isoniazid alone for nine months.

Nine months of a drug for a disease you don't even feel like you have?

I can see where adherence might be a problem.

It is a huge problem.

Adherence is the Achilles heel of TB control.

The text addresses this by discussing DOT directly observed therapy.

DOT.

This isn't just a suggestion.

It's a protocol where a health care provider literally watches the patient swallow the pills.

It sounds intrusive, but given the stakes.

It's necessary.

Because the treatment is long and the drugs have side effects, patients often stop taking them once they feel better.

But if they stop early, the dormant bacteria wake up and now they might be resistant.

The text also mentions intermittent dosing to help with this.

Right.

Instead of daily pills, you might dose two or three times a week, but at higher doses.

This makes supervision easier and cheaper.

However, the text puts a big red flag here.

You generally do not do intermittent dosing for patients with advanced HIV.

They need daily therapy because their immune system can't help hold the line between doses.

Let's talk about the nightmare scenario.

Resistance.

We have MDR -TB and XDR -TB.

Can you define those based on the text?

Okay.

So MDR -TB stands for multi -drug resistant TB.

This is defined specifically as resistance to at least isoniazid and rifampin are two best drugs.

If you lose those, you're fighting with one hand tied behind your back.

Okay.

And XDR.

XDR -TB is extensively drug resistant.

That means it's MBR, so it's resistant to isoniazid and rifampin, PLO2S.

It's resistant to fluoroquinolones and at least one of the injectable second line drugs.

And the implication of that is?

It's grim.

Treatment extends to two years.

The drugs are more toxic, less effective, and many cases are fatal.

The text emphasizes that preventing this through adherence is far, far better than trying to treat it.

All right.

Let's get into the weapons themselves.

We are going to break down the first line drugs one by one.

First up is the MVP,

isoniazid, or INH.

The mainstay of treatment for 60 years.

If you learn one drug from this chapter, learn isoniazid.

The text goes deep into the pharmacokinetics and genetics here.

This seems like prime exam material.

It talks about acetylation.

Explain this process.

Okay.

Let's unpack this.

Isoniazid is absorbed well, but it needs to be cleared from the body.

It is metabolized or broken down in the liver.

The enzyme that does this is called N -acetyltransferase.

N -acetyltransferase.

And here is where it gets interesting.

The activity of this enzyme is genetically determined.

So depending on your genes, you might have a fast enzyme or a slow enzyme.

Exactly.

It's what we call a genetic polymorphism.

You're either a slow acetylator or a fast acetylator.

And slow acetylation is an autosomal recessive trait.

There is a figure in the book, figure 41 .1, that shows a bimodal distribution.

Can you describe what that looks like for the listener who doesn't have the book open?

Sure.

Imagine a graph with two distinct hills or humps, kind of like a camel.

On the bottom axis, you have the plasma concentration of the drug.

On the vertical axis, you have the The first hump, on the left, represents the fast acetylators.

They metabolize the drug quickly, so they have lower plasma drug levels.

The second hump, on the right, represents the slowest acetylators.

They metabolize it slowly, so the drug hangs around longer, leading to higher drug levels.

And the text links this to ethnicity, right?

It does.

It notes that the fast phenotype predominates in Japanese and Inuit populations.

The slow phenotype is more common in Middle Eastern, Scandinavian, and North African populations.

In the US, it's roughly a coin toss.

About 50 % are slow, 50 % are fast.

So what does this mean for the patient if I'm a slow acetylator?

Is that good or bad?

It's a double -edged sword, but mostly it's a risk factor.

Because you have higher drug levels, you are more prone to toxicity.

Fast acetylators respond well to bacteria, but they have lower levels.

The text emphasizes that slow acetylators are specifically more prone to the peripheral neuropathy side effect, which we'll discuss in a moment.

Moving to the mechanism of action.

How does isoniazid actually kill the bacteria?

We mentioned the cell wall earlier.

Right.

It targets that mycolic acid layer.

Specifically, it inhibits the synthesis of mycolic acid.

Without mycolic acid, the mycobacteria cannot build their unique cell wall.

It becomes unstable and the cell dies.

But there is a quest.

Isoniazid is a pro -drug.

What does that mean?

It means that in the pill bottle, it's inactive.

It has to be activated inside the bacteria.

The bacteria have an enzyme called catalase peroxidase.

This enzyme is encoded by the KG gene.

KG?

This enzyme activates isoniazid, turning it into the toxic molecule that stops the cell wall production.

So if the bacteria want to become resistant?

They mutate the KG gene.

They essentially turn off the switch that activates the drug.

If the drug isn't activated, it can't kill them.

Wow.

That is the primary mechanism of a simple genetic deletion makes the drug useless.

Fascinating.

So KG mutation equals isoniazid resistance.

Now let's talk adverse effects.

What happens when things go wrong with INH?

Two big ones you need to memorize.

First, hepatotoxicity.

It damages the liver.

The text mentions that this is strictly age -dependent.

If you are under 35, the risk is quite low.

If you are over 50, the risk becomes high.

So for a 20 -year -old student, probably fine.

For a 60 -year -old patient, you need to watch those liver enzymes like a hawk.

Precisely.

You monitor serum transaminases.

If they spike, you have to stop the drug before you get clinical hepatitis.

And the second major side effect is peripheral neuritis.

This presents as paresthesia,

so numbness and tingling, usually in the fingers and toes.

And this is caused by a vitamin deficiency.

Yes.

This is a crucial mechanism.

Isoniazid binds to which is vitamin B6 and promotes its excretion.

It basically strips B6 out of your body.

And without B6, your nerves start to degrade.

And the fix?

Supplements.

You give 25 to 50 milligrams of vitamin B6 orally every day along with the drug.

And this risk is higher in our slow acetylators because they have more drug floating around in activating the vitamin.

All right.

That's isoniazid.

Let's move to the next two in the combo.

Let's start with ethambutol.

What's its job?

Ethambutol also attacks the cell wall, but a different part.

It inhibits an enzyme called aerabinosal transferase.

Aerabinosal transferase.

Say that five times fast.

I'd rather not.

But what it does is stop the formation of the aerabinogalactin layer of the cell wall.

The text suggests this increases the permeability of the cell wall.

But it's like poking holes in the mortar so the other drugs can get in better.

That's a great way to think about it.

Now for the last minute lecture, high yield alert.

The side effects of ethambutol.

There is one classic exam question here.

Oh, yes.

Optic neuritis.

This is damage to the optic nerve.

But specifically, it causes impaired red -green color discrimination.

So the patient might start having trouble distinguishing stoplights?

Exactly.

Or colors just look washed out.

It's dose dependent.

If a patient on TB med starts complaining about their vision, you merely check if they are on ethambutol.

Is it reversible?

It is usually reversible if you stop the drug.

But if you don't catch it, it can be permanent.

It also mentions hyperuricemia.

Yes.

Which can lead to gout.

It decreases the kidney's ability to excrete uric acid.

So joint pain is a possibility.

Okay.

Pyrazenomide.

The text calls it an important drug because it allowed treatment to drop from 9 -12 months down to 6 months.

How does it do that?

It's the accelerator.

It has a unique sterilizing effect.

While isoniazade kills the growing bacteria, pyrazenomide is really good at killing the non -growing organisms hiding in that acidic environment of the macrophage or the necrotic lesion.

The cheese bunker.

Exactly.

The cheese bunker is acidic.

Pyrazenomide acts best at an acidic pH.

And its mechanism?

It's converted to pyrazenoic acid by an enzyme called pyrazonamidase.

This acid inhibits fatty acid synthesis, disrupting the cell membrane stability.

Side effects for pyrazenomide.

Arthrogyl, which is joint pain, is very common.

And again, hyperuricemia and gout.

Both ethambutol and pyrazenomide can cause gout attacks.

And the liver.

It can also be hepatotoxic, so it adds to the liver strain caused by isoniazade and refampin.

Okay.

That leaves the heavyweight champion of the antibiotics world, refampin.

Refampin is a powerhouse.

Unlike the others, which are synthetic, this is a derivative of a natural antibiotic produced by a mold.

Mechanism of action.

It goes for the control center.

It binds to the beta subunit of DNA -dependent RNA polymerase.

Translate that for us.

It stops the bacteria from making RNA.

It blocks the process of transcription.

No RNA means no proteins.

No proteins means cell death.

But it doesn't do that to our cells.

No.

And this is important.

It does not bind to human RNA polymerase, so it doesn't shut down our cells.

That selectivity is key.

The spectrum seems broader than the others.

Much broader.

It hits gram -positives, gram -negatives, and all the acid -fast bugs TB, MAC, leprosy.

It's also used for prophylaxis and meningitis, which we can touch on later.

But the text has a bold warning.

Never use refampin as monotherapy for active infections.

Why?

Resistance develops incredibly fast.

The text says microbes acquire resistance quickly if it's used alone.

It only takes a single -point mutation in that polymerase enzyme to change its shape so the drug can't bind.

So you select for that mutant almost immediately.

Exactly.

So always combine it.

Now the side effects, there is one that is startling if you aren't expecting it.

The orange warning.

Refampin and its metabolites are reddish -orange dyes.

It discolors everything.

Saliva, tears, urine, sweat.

Everything turns reddish -orange.

And it stains contact lenses.

Permanently.

If you cry orange tears into your soft contacts, they are ruined.

You have to warn patients about this, or they will think they are bleeding from their eyes.

Aside from the cosmetic issues, there is a massive pharmacological issue with refampin.

Drug interactions.

This is probably the most complex part of the chapter.

This is critical.

Refampin is a potent inducer of the cytochrome P450 system.

Specifically, the text lists CYP1A2, CYP2C9, and CYP3A4.

Okay, inducer means speed up.

Right.

It revs up the liver's metabolic engines.

The liver chews up other drugs much faster than normal.

The text lists some victims of this induction.

Warfarin, which is a blood thinner.

Oral contraceptives.

Degoxin for the heart.

And crucially, HIV protease inhibitors.

Let's play that out.

If a woman is on the birth control pill and starts taking refampin for TD.

The refampin tells the liver to destroy the hormones in the pill.

The levels drop, and she could get pregnant while on TB treatment.

Wow.

Okay.

And for the HIV patient.

This is the co -epidemic problem again.

If you give them refampin, it chews up their HIV meds, specifically the protease inhibitors.

The HIV virus roars back.

It's a pharmacological nightmare.

Which is why we often swap refampin for a substitute in HIV patients.

Let's look at part six.

Second line.

Alternative.

And new drugs.

Let's pick up on that substitute.

A fabentin.

Rifabutin is a cousin of refampin.

It's in the same family the rifamycins.

But its superpower is that it induces those CYT enzymes less than refampin does.

So it doesn't mess up the HIV drugs as badly?

Correct.

It's the preferred choice for TB patients who were also HIV positive and on protease inhibitors.

It allows us to treat both diseases simultaneously without torpedoing the HIV therapy.

And rifapentime.

Another cousin.

It's longer acting.

It has a longer half -life.

So it's used in those twice -weekly regimens we mentioned earlier to help with adherence.

The text then lists the injectables.

Streptomycin, amikacin, canamycin.

These are aminoglycosides.

Yes.

Old -school antibiotics.

They inhibit protein synthesis at the 30S ribosome.

They're used when we suspect resistance to the first -line drugs.

But they're not ideal.

Oh, they have to be injected intramuscularly, which is painful and difficult for a long course.

And they are toxic to the ears, ototoxicity, and kidneys, nephrotoxicity.

Now let's talk about the breakthroughs.

The text says there was a 40 -year gap where we had no new TB drugs.

Then came bedaquiline.

Bedaquiline is a big deal.

It's the first unique TB drug in decades.

Its mechanism is fascinating.

It blocks the proton pump for ATP synthase.

It cuts off the power supply.

Exactly.

It stars the bacteria of energy, or ATP.

It works specifically on the mycobacterial ATP synthase, not the human one.

But as always, there's a catch.

A black box warning.

A scary one.

It prolongs the QT interval on the ECG.

That's the heart's electrical resetting time.

Right.

It blocks the AGRG potassium channel in the heart.

If that interval gets too long, it can lead to fatal arrhythmias like torsades de pointes.

So this isn't a drug you use lightly.

Not at all.

If you put a patient on bedaquiline, you need regular ECGs.

It is reserved for MDRTB because of this risk.

And the other new kit on the block is predomanded.

Predomanded.

Also for resistant TB, either XDR or MDR.

It's usually used in a specific three -drug combo with bedaquiline and lanusolid.

It has a dual mechanism.

It blocks mycolic acid biosynthesis like isoniazid.

But it also releases reactive nitrogen species to poison the cell.

It's amazing to see how much effort goes into cracking that cell wall and killing these bugs.

It is a constant arms race.

Okay, moving on to part seven.

We've done TB.

Now let's look at the treatments for M, MN, and leprosy.

For MS, M -AVM intracellular heller, we mentioned it's common in HIV patients.

How do we treat it?

Well, we have two strategies, prophylaxis and treatment.

For prophylaxis, so preventing it before it starts in an AIDS patient, we use macrolides, specifically azithromycin or clarithromycin alone.

But if they have the active infection.

Then it's a cocktail.

You never treat active mycobacterial infection with one drug.

For active AMC, it's usually a macrolide like clarithromycin, PLEO -US, ethambutol, PLOS, rifabutin.

Got it.

Now, leprosy, Hansen disease.

The text highlights a drug called Dapsone.

Dapsone is the foundation of leprosy therapy.

It's a sulfone.

Mechanism.

It inhibits folic acid synthesis.

Specifically, it inhibits an enzyme called dihydropterote synthase.

It's actually very similar to the sulfonamide antibiotics used for UTIs.

It starves them of Foley.

Which they need to make DNA.

The text says it is bacteriostatic.

It stops them from growing, but doesn't necessarily kill them outright on its own.

And the side effects.

I see hemolytic anemia listed.

Yes.

Specifically in patients with G6PD deficiency.

This is genetic enzyme deficiency.

If those patients take Dapsone, the drug causes oxidative stress on their red blood cells.

Without the G6PD enzyme to protect them, the cells burst.

And that leads to severe anemia.

Yep.

That's a keyboard question right there.

G6PD and Dapsone.

It also causes peripheral neuropathy.

To make the regimen more effective, we add rifampin.

Yes.

Rifampin is the most bactericidal drug against M.

leprae.

It does the heavy killing in the leprosy regimen.

And then there's this third drug, clofazamine.

This one sounds like a dye.

It is a phenazine dye.

It works by binding to DNA and has some anti -inflammatory properties.

And the side effect reflects that it's a dye.

It's startling.

It causes skin discoloration.

The skin turns red -brown to nearly black.

It also discolors bodily secretions.

And the text says it accumulates in tissues.

It has a half -life of 70 days.

That is immense.

It dissolves in the body fat and stays there for months or years.

The skin discoloration can persist long after treatment stops.

Wow.

Finally, there is a drug with a notorious history listed under leprosy.

Gallitamide.

The redemption arc.

Paldimide was banned in the 60s because it caused focumelia -severe limb defects in babies when pregnant women took it for morning sickness.

But it's back.

It has orphan drug status.

It's used for a specific complication of leprosy called erythema, nodosum -liprosum, or ENL.

It's a painful hypersensitivity reaction where the immune system goes into overdrive attacking the dead bacteria.

Thalidomide modulates the immune system, stimulates T -cells, and helps control this reaction.

Obviously, strictly contraindicated in pregnancy.

Strictly.

The controls on prescribing it are tighter than almost any other drug.

All right.

We have covered a massive amount of ground.

We've gone from the alveolar macrophage to the QT interval.

Let's head into the outro and summarize the big pictures for the student listener who is frantically taking notes.

OK.

Let's condense this.

Big picture summary.

One, TB and leprosy are chronic.

You need long -term multi -drug therapy to penetrate granulomas and kill dormant bugs.

Two, isoniazid, INH, targets mycolic acid, needs KG to work.

Watch out for the liver, so hepatitis, and the nerves, so get B6.

And remember the genetics of acetylation.

Right.

Three, rifampin.

Targets RNA polymerase, turns fluids orange, revs up the liver.

That's the CYP inducer, so it eats other drugs like HIV meds and warfarin.

Got it.

Four, parazenamide, the accelerator, goes into the acid bunker.

Watch out for GAP.

And number five.

Five,

ethambutyl targets the cell wall.

Watch out for the eyes,

red -green color blindness.

And for the resistant cases.

You bring in the big guns like bedaquiline, the ATP synthase blocker, but watch the heart for that QT prolongation.

Fantastic.

Now, the text ends with some review questions.

Let's test our listeners.

I'll ask, you give the answer, and a brief why.

Let's do it.

Question one.

Which drug is recommended for treatment of most persons with latent TB?

That would be isoniazid.

Nine months is the standard monotherapy.

Question two.

Which drug inhibits RNA polymerase in mycobacteria?

Rifampin.

Remember, R for RNA.

Question three.

A woman being treated for a mycobacterial infection develops optic neuritis.

Which agent caused it?

Ethambutyl.

E for I.

Question four.

Mutations to the KG gene confer resistance to which agent?

Isoniazid.

No KG enzyme, no drug activation.

And finally, persons with high acetyltransferase activity, the fast acetylators, will have lower plasma levels of which drug?

Isoniazid again.

They chew it up faster.

Well, there you have it.

Chapter 41, decoded.

It's a dense chapter, but if you categorize the drugs by their target cell wall, DNA,

energy, it starts to make sense.

What I love about this chapter is how it's not just a list of drugs.

It's really a story about strategy.

You have to understand the enemy, how it hides, how it resists, before you can understand the weapons you're using against it.

That's a great point.

It's a game of chess.

The granuloma is the bacteria's castle.

Some drugs are for storming the walls, some are for starving them out, and some are for poisoning the well.

Let's go back to Rifampin and CYP induction for a minute, because this is so clinically important.

You mentioned warfarin.

If a patient is on wolfrin and you start them on Rifampin, you said you'd have to increase the dose.

How much are we talking?

It can be a massive adjustment.

You're constantly checking their blood clotting time, their INR, and titrating the warfarin dose up, sometimes doubling it or more, just to keep them in a therapeutic range.

And then, when you stop the TB treatment six months later, you have to be right on top of it.

As the induction wears off and the liver metabolism slows back to normal, if you don't cut that warfarin dose back down immediately,

their INR will shoot through the roof.

And they're at a huge risk of bleeding.

A huge risk.

A brain bleed, a GI bleed.

It's a very dangerous transition period.

It really highlights why the pharmacist and physician have to be communicating.

It's not just take these pills for six months.

It's six months of active management.

Absolutely.

The text mentions that DOT, directly observed therapy, is recommended.

That's not just about watching them swallow.

It's a daily touch point to ask, hey, are your eyes hurting?

Are your joints hurting?

Are you taking any new meds?

Let's revisit the bedacoline QT prolongation.

The text says it blocks the HRRG potassium channel.

Why is that channel so vulnerable?

So many drugs seem to affect it.

It's a quirk of its structure.

The HRRG channel has a large inner vestibule that can trap a wide variety of drug molecules, ones that are basic and have a certain shape.

It wasn't designed to be a drug trap.

It's just an unfortunate coincidence of molecular biology.

So it's not that bedacoline was designed to hit it.

Not at all.

It's an off -target effect, but it's a life -threatening one.

That's why with any new drug development, HRRG channel testing is one of the first and most important safety screens they do.

You know, it occurs to me that the side effect profiles of these drugs almost tell a story about the patient's experience.

You've got potential liver damage, nerve tingling, joint pain, vision changes, orange tears.

That's before you even get to the second line drugs.

It's a grueling regimen.

This isn't like taking an antibiotic for a week for a sinus infection.

It's a long, hard road, which again speaks to why adherence is such a challenge.

What about the future?

The text mentions these two new drugs, but are we just waiting for another 40 -year drought?

Hopefully not.

The rise of XDRTB has really re -energized the field.

There's a lot more research now into drugs with novel mechanisms.

The goal is to find regimens that are shorter, safer, and effective against resistance strains.

The dream is a one -month pill that cures everything.

But we're not there yet.

We are not there yet.

For now, it's the R .I .P .E.

regimen and careful monitoring.

Okay, let's try a quick mnemonic review for the main toxicities just to lock it in.

Let's do it.

Rifampin.

Red -orange fluids, and it revs up the liver.

Isoniazid.

Injures neurons and hepatocytes.

Oh, that's good.

INH.

Perfect.

Pyrazinamide.

Hyperuricemia, so pain in the joints.

And ethambutol.

Eyes.

It's all about the eyes.

I think that's incredibly helpful.

Before we wrap up, what's one final thought you'd want a student to take away from this deep dive, something to mull over after the exam is done?

I think it's the concept of selective toxicity.

Every drug in this chapter works because it targets something in the mycobacteria that is different from us.

A different cell wall, a different RNA polymerase, a different ATP synthase.

Pharmacology is the art of finding those differences and exploiting them.

It's about how to kill the invader without killing the host.

A fantastic point to end on.

It's the whole foundation of the science.

It is.

Well, I think we have squeezed every drop of knowledge out of chapter 41.

We've covered the bugs, the drugs, the genes, and the side effects.

And we stayed strictly within the text.

We did no Googling allowed.

To you listening,

if you can master these concepts,

mechanism, resistance, toxicity, and those crucial drug interactions, you're going to crush this section of your exam.

And more importantly, you'll understand how to treat a disease that has plagued humanity for millennia.

Hear, hear.

Thanks for joining the last minute lecture team on this deep dive.

Good luck with your studies, ace that exam, and we will catch you on the next one.

Goodbye.